CervoMed Announces $50M Sales Agreement with Leerink

CervoMed ( (CRVO) ) has shared an announcement.

On May 12, 2025, CervoMed Inc. announced a sales agreement with Leerink Partners LLC to offer and sell up to $50 million in common stock. This agreement allows for ‘at-the-market’ offerings through various trading markets, with Leerink Partners acting as the sales agent. CervoMed also reported positive 16-week results from the Phase 2b RewinD-LB trial, showing proof-of-concept for neflamapimod as a treatment for DLB. The company plans to initiate a Phase 3 trial in mid-2026 and is conducting additional trials for other neurological conditions, supported by a $21.3 million grant from the National Institute on Aging.

The most recent analyst rating on (CRVO) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on CervoMed stock, see the CRVO Stock Forecast page.

Spark’s Take on CRVO Stock

According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.

CervoMed’s primary challenges stem from its lack of revenue and persistent financial losses, which heavily weigh down its stock score. However, positive technical indicators and recent promising clinical trial results provide a speculative upside, balancing some of the financial concerns. Valuation remains a challenge due to negative earnings, but the potential for future success in clinical trials offers hope for long-term growth.

To see Spark’s full report on CRVO stock, click here.

More about CervoMed

CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The company is currently developing neflamapimod, an investigational, orally administered small molecule that targets synaptic dysfunction in diseases like dementia with Lewy bodies (DLB) and other neurological disorders.

Average Trading Volume: 4,911,265

Technical Sentiment Signal: Sell

Current Market Cap: $73.89M

See more insights into CRVO stock on TipRanks’ Stock Analysis page.